David L Knight

1.7k total citations
30 papers, 1.4k citations indexed

About

David L Knight is a scholar working on Cellular and Molecular Neuroscience, Biological Psychiatry and Molecular Biology. According to data from OpenAlex, David L Knight has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cellular and Molecular Neuroscience, 8 papers in Biological Psychiatry and 5 papers in Molecular Biology. Recurrent topics in David L Knight's work include Tryptophan and brain disorders (8 papers), Neuroscience and Neuropharmacology Research (7 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). David L Knight is often cited by papers focused on Tryptophan and brain disorders (8 papers), Neuroscience and Neuropharmacology Research (7 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). David L Knight collaborates with scholars based in United States, Australia and Germany. David L Knight's co-authors include Charles B. Nemeroff, Michael J. Owens, Pamela R. Getson, Lawrence M. Rudner, James Ritchie, V. R. Hensley, Brent Waters, Kelly Skelton, Marisol Vargas and W. Edward Craighead and has published in prestigious journals such as Journal of Neuroscience, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

David L Knight

29 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David L Knight United States	18	435	306	292	248	239	30	1.4k
Leighton Y. Huey United States	22	316 0.7×	195 0.6×	188 0.6×	412 1.7×	104 0.4×	54	1.3k
Joel A. Posener United States	17	243 0.6×	433 1.4×	257 0.9×	394 1.6×	341 1.4×	27	1.5k
J. E. Christie United Kingdom	20	289 0.7×	206 0.7×	422 1.4×	501 2.0×	149 0.6×	42	1.9k
Tai‐Jui Chen Taiwan	23	649 1.5×	236 0.8×	239 0.8×	285 1.1×	320 1.3×	39	1.6k
Masahiro Asai Japan	21	269 0.6×	214 0.7×	101 0.3×	390 1.6×	270 1.1×	51	1.3k
Mitsuhiro Kamata Japan	22	514 1.2×	159 0.5×	441 1.5×	430 1.7×	296 1.2×	58	1.4k
Christoph Spindelegger Austria	18	421 1.0×	181 0.6×	258 0.9×	248 1.0×	130 0.5×	34	1.5k
Sandra Sagrati Canada	10	520 1.2×	150 0.5×	498 1.7×	279 1.1×	302 1.3×	10	1.7k
Ursula Havemann‐Reinecke Germany	23	492 1.1×	499 1.6×	376 1.3×	238 1.0×	261 1.1×	68	1.8k
Keith G. Kramlinger United States	13	313 0.7×	136 0.4×	298 1.0×	649 2.6×	126 0.5×	17	1.5k

Countries citing papers authored by David L Knight

Since Specialization

Citations

This map shows the geographic impact of David L Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L Knight more than expected).

Fields of papers citing papers by David L Knight

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L Knight. The network helps show where David L Knight may publish in the future.

Co-authorship network of co-authors of David L Knight

This figure shows the co-authorship network connecting the top 25 collaborators of David L Knight. A scholar is included among the top collaborators of David L Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L Knight. David L Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Newport, D. Jeffrey, Michael J. Owens, David L Knight, et al.. (2004). Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. Journal of Psychiatric Research. 38(5). 467–473. 34 indexed citations

Owens, Michael J., David L Knight, & Charles B. Nemeroff. (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological Psychiatry. 50(5). 345–350. 415 indexed citations

Knight, David L. (2001). CRUISING 2001: A PIONEER IN THE REBIRTH OF THE GREAT LAKES CRUISE INDUSTRY BUILDS ON ITS SUCCESSES..

Owens, Michael J., David L Knight, & Charles B. Nemeroff. (2000). Paroxetine binding to the rat norepinephrine transporter in vivo. Biological Psychiatry. 47(9). 842–845. 55 indexed citations

Kilts, Clinton D., David L Knight, & Charles B. Nemeroff. (1996). The simultaneous determination of neurotensin and its major fragments by on-line trace enrichment HPLC with electrochemical detection. Life Sciences. 59(11). 911–920. 3 indexed citations

Owens, Michael J., Cynthia A. Ballenger, David L Knight, & Charles B. Nemeroff. (1996). Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat.. Journal of Pharmacology and Experimental Therapeutics. 278(3). 1040–1049. 12 indexed citations

Krishnan, Kousik, Larry A. Tupler, James Ritchie, et al.. (1996). Apolipoprotein E-ε4 frequency in geriatric depression. Biological Psychiatry. 40(1). 69–71. 96 indexed citations

Owens, M J, et al.. (1995). The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studies. Life Sciences. 57(24). PL373–PL380. 24 indexed citations

Nemeroff, Charles B., David L Knight, John Franks, W. Edward Craighead, & K. Ranga Krishnan. (1994). Further studies on platelet serotonin transporter binding in depression. American Journal of Psychiatry. 151(11). 1623–1625. 82 indexed citations

10.

Nemeroff, Charles B., David L Knight, & Garth Bissette. (1992). SOMATOSTATIN: A NEUROPEPTIDE SYSTEM PATHOLOGICALLY ALTERED IN ALZHEIMERʼS DISEASE AND DEPRESSION. Clinical Neuropharmacology. 15. 311A–312A. 10 indexed citations

11.

Steege, John F., Anna L. Stout, David L Knight, & Charles B. Nemeroff. (1992). Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. American Journal of Obstetrics and Gynecology. 167(1). 168–172. 31 indexed citations

12.

Husain, Mustafa M., David L Knight, P. Murali Doraiswamy, et al.. (1991). Platelet [3H]-imipramine binding and leukoencephalopathy in geriatric depression. Biological Psychiatry. 29(7). 665–670. 14 indexed citations

13.

Owens, Michael J., Marisol Vargas, David L Knight, & Charles B. Nemeroff. (1991). The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal.. Journal of Pharmacology and Experimental Therapeutics. 258(1). 349–356. 87 indexed citations

14.

Knight, David L, et al.. (1991). Some aspects of nutrient chemistry of the Caribbean Sea. 5 indexed citations

15.

Peter, James B., et al.. (1990). Is decreased imipramine binding by platelet membranes in major depression associated with plasma autoantibodies to imipramine binding sites?. Biological Psychiatry. 28(4). 365–368. 4 indexed citations

16.

Owens, Michael J., David L Knight, James Ritchie, & Charles B. Nemeroff. (1990). The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brain.. Journal of Pharmacology and Experimental Therapeutics. 256(2). 787–794. 34 indexed citations

17.

Owens, M J, David L Knight, James Ritchie, & Charles B. Nemeroff. (1990). The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.. Journal of Pharmacology and Experimental Therapeutics. 256(2). 795–800. 22 indexed citations

18.

Slotkin, Theodore A., William L. Whitmore, K. Ranga R. Krishnan, et al.. (1989). Reduced inhibitory effect of imipramine on radiolabeled serotonin uptake into platelets in geriatric depression. Biological Psychiatry. 25(6). 687–691. 18 indexed citations

19.

Kilts, Clinton D., David L Knight, Richard B. Mailman, E. Widerlöv, & George R. Breese. (1984). Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine.. Journal of Pharmacology and Experimental Therapeutics. 231(2). 334–342. 35 indexed citations

20.

Lewis, Mark H., E. Widerlöv, David L Knight, Clinton D. Kilts, & Richard B. Mailman. (1983). N-oxides of phenothiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic function.. Journal of Pharmacology and Experimental Therapeutics. 225(3). 539–545. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact